<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>structural variant analysis in oncology &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/structural-variant-analysis-in-oncology/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Wed, 01 Oct 2025 19:29:05 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>structural variant analysis in oncology &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>MSK Researchers Pioneer Innovative Method to Investigate Treatment Resistance in High-Grade Serous Ovarian Cancer</title>
		<link>https://bioengineer.org/msk-researchers-pioneer-innovative-method-to-investigate-treatment-resistance-in-high-grade-serous-ovarian-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 01 Oct 2025 19:28:48 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[CloneSeq-SV technology]]></category>
		<category><![CDATA[High-grade serous ovarian cancer]]></category>
		<category><![CDATA[liquid biopsy innovations]]></category>
		<category><![CDATA[structural variant analysis in oncology]]></category>
		<category><![CDATA[treatment resistance mechanisms]]></category>
		<guid isPermaLink="false">https://bioengineer.org/msk-researchers-pioneer-innovative-method-to-investigate-treatment-resistance-in-high-grade-serous-ovarian-cancer/</guid>

					<description><![CDATA[High-grade serous ovarian cancer (HGSOC) remains one of the most lethal gynecologic malignancies, owing to its tendency for early microscopic dissemination within the abdominal cavity and its relentless recurrence following initial therapy. Despite advances in surgical techniques, chemotherapeutic regimens, and maintenance strategies, the majority of patients with advanced disease eventually experience tumor relapse, underscoring an [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">274625</post-id>	</item>
	</channel>
</rss>
